Glutathione

Glutathione Regulatory Status

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Glutathione holds no marketing authorisation as a medicine from the MHRA, EMA or FDA. Intravenous use for cosmetic skin lightening has drawn specific regulatory attention in several jurisdictions, which is unusual for a compound otherwise treated as a nutrient.

Key facts

MHRA medicine status
Not authorised
EMA medicine status
Not authorised
FDA drug status
Not approved
Cosmetic IV use
Regulatory attention in several jurisdictions
Supply basis here
Laboratory research only
Claim pressure
Cosmetic, not therapeutic

The position

No regulator has authorised glutathione as a medicine. It occupies an ambiguous space, a naturally occurring compound present in food and in every cell, sold in some jurisdictions as a supplement, and used cosmetically in ways that have attracted regulatory warnings.

Why the intravenous route changed the picture

A compound consumed in food raises few regulatory questions. Administering it intravenously for a cosmetic purpose is a different proposition. It bypasses every barrier the digestive route imposes, at doses food never delivers, for an outcome that is not a medical need. That combination is what drew attention, and it is why the 2025 Cureus review foregrounds safety.

Research material referenced

Glutathione 1500mg, third-party HPLC tested

Buy Glutathione · £38.99

The claim boundary here

This category's pressure is cosmetic rather than therapeutic, which does not make it lower. Skin-lightening claims are regulated, and the fact that a systematic review exists does not license repeating its subject matter as a product claim. Describing a literature and making a claim remain different acts.

What is said on this site

That glutathione is a gamma-linked tripeptide at 307.33 Da, that it is the principal cellular thiol antioxidant, that Richie 2015 reported increased body stores with oral supplementation, and that two 2025 systematic reviews examined the skin literature including its safety. Not said: that this product lightens skin, treats melasma, detoxifies anything, or affects any condition in any person.

The enforcement context

The MHRA opened investigations into UK retailers making therapeutic claims about unregulated products in April 2026. The framework turns on the claim and intended use. A compound that is simultaneously a nutrient, a supplement and a cosmetic ingredient in different contexts is regulated here on the basis of how it is presented.

Frequently asked questions

Is glutathione approved as a medicine?

No, in any jurisdiction. Some supplement frameworks permit sale, which assesses safety for consumption rather than efficacy.

Why has intravenous use drawn regulatory attention?

It bypasses digestive barriers at doses food never delivers, for a cosmetic rather than medical purpose. A combination regulators have examined.

Can a systematic review be cited as a product claim?

No. Describing what a literature examined and claiming a product does it are different acts, and only the first is permissible here.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Glutathione articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.